LA JOLLA, Calif., Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from ATHENA, its global natural history of disease study for Alport syndrome, at the American Society of Nephrology's (ASN) Kidney Week 2018 meeting being held October 23-28, 2018 in San Diego, CA.
Poster Presentations October 26, 2018, 10:00AM – 12:00PM:
- Abstract 3024711: Quality of Life Changes as Measured with SF-36 in Patients with Alport Syndrome: Results from the ATHENA Natural History Study in Alport Syndrome Patients.
- Abstract 3024235: Urine and blood biomarkers correlate with rate of eGFR decline in Alport syndrome.
"We are very proud of the work that has gone into completing this large natural history of disease study for Alport syndrome patients. This study has provided valuable information to better characterize the natural progression of Alport syndrome, which to date has not been well understood. These presentations are the culmination of a significant effort by our network of investigators and study participants together with the team at Regulus to help better define this challenging and rare kidney disorder, and inform future clinical development plans for this disease," said Jay Hagan, President and Chief Executive Officer of Regulus.
About the ATHENA Study
The ATHENA study was a natural history of disease study designed to characterize the natural decline of renal function markers such as Glomerular Filtration Rate ("GFR"), creatinine, proteinuria and beta-2 microglobulin, in Alport syndrome patients over time. The data collected from the ATHENA study provided important information about the changes in renal function over time in Alport syndrome patients, which will inform future clinical development plans for this disease.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA. For more information, please visit http://www.regulusrx.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain goals and objectives. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
SOURCE Regulus Therapeutics Inc.